# **Index to Volume Eleven**

Index of Issues: January-March 1-58; April-June 59-118; July-September 119-184; Supplement to July-September 185-266; October-December 267-330; Supplement to October-December 331-470.

# **INDEX OF AUTHORS**

A	D	Holmes KK, 77, 159, 291	Mallinson H, 10
		Hook EW III, 77	Mangioni C, 444
Akaydin A, 416	D'Costa LJ, 72, 304, 376	Househ JG, 156	Marca G, 444
Aksoy M, 347	Daems A, 456	Hubrechts J-MH, 456	March P-A, 366, 428
Alessi E, 407	de Hoop D, 379		Mascaro JM, 396
Alexander WJ, 156	De Goes Siqueira LF, 422	1	McCormack WM, 81, 185
Alfa MJ, 131	de Parra CS, 425		Medina JS, 425
Altinok T, 414	den Boer MS, 379	Ilako F, 376	Miller JN, 275
Andrews BE, 10	Dessens-Kroon M, 364		Mirza N, 72
Ariyarit C, 404	Dillon J-AR, 353	)	Monti M, 407
Arya OP, 10	Dincol G, 347	•	Moore J, 271
Ashton FE, 296	dos Santos MFQ Jr, 420, 422	Jequier N, 398	Moroni M, 444
	Drummond L, 1	Jones RB, 287	Mumtaz G, 432
В	Duangmani C, 148		The state of the s
	Dubreuil D, 296	K	Murat A, 414
Bakioglu I, 347	Dylewski J, 6		
Beaudet R, 296		Kampmeier RH, 41, 169, 186,	N
Belda W, 420, 422	E	188, 197, 200, 228, 318	Ndinya-Achola, 376
Belda W Jr, 420	-	Karasira P, 72, 304	Noble RC, 24, 68, 152
Bell TA, 291	Echeverria P, 148	Kerbs SB, 28, 30	
Berg SW, 28, 30, 314	Eisen R, 34	Kerbs SBJ, 314	Norris SJ, 275
Bhutani LK, 164	Embree J, 81	Kilpatrick ME, 314	Notowicz A, 379
Bisaillon J-G, 296	Erdem S, 347	Kim J-H, 386	Nsanze H, 6, 72, 304, 376
Black JR, 96		Knapp JS, 77	
Bohbot J-M, 391	F	Komaroff AL, 123	0
Bollerup AC, 308		Kouri YH, 91	O'Connor R, 148
Borchardt KA, 59	Fagundes LJ, 422	Kraiselburd EN, 91	
Bovet R, 398	Fast MV, 72	Krieger J, 173	O'Hare M, 432
Braun P, 123	Felmingham D, 410, 432	Krieger JN, 100	Oran M, 414
Britt EM, 301	Fennell CL, 18	Kristensen JK, 32	Oriel JD, 410
Butzler J-P, 456	Ferrari V, 336	Kumar AS, 164	Ortega HB, 59
Bygdeman SM, 366	Ferrer RM, 91	Kunz J, 449	Ortega P, 59
2,844	Finegold SM, 430		Ortisi G, 444
С	Fiumara NJ, 34, 267	Kutlar A, 347	Ostrow DG, 182
C	Francisco W, 422		Owili DM, 376
Calanchini E, 398	Tablesoo II, Iaa	L	
Caliando JJ, 81	_	Lambert M, 36	P
Calubiran OV, 382	G	Lancaster DJ, 30	D 11: DV 144
Capdevila JM, 396	Gerson M, 85	Latif AS, 454	Pandhi RK, 164
Carlson BL, 312	Giz H, 414	Lencioni R, 454	Panikabutra K, 148, 404
Catalan F, 391	Graves S, 1		Pappius EM, 123
Cates W Jr, 113	Griffith H, 156	Lhuillier N, 391	Parekh MC, 68, 152
Causse GY, 333	Official 11, 150	Lind I, 360	Pauze M, 353
Chitwarakorn A, 404		Lombardi C, 422	Petzoldt D, 468
Cohen Al, 24	н	Loo PSL, 410	Piot P, 6, 72, 376
Cohen MS, 96	Haley JV, 68	Lovett MA, 275	Pitarangsi C, 148
Conant MA, 94	Haley MS, 312		Plummer FA, 6, 304
Cooperative Study Group for	Hamelin C, 85	M	Portnoy J, 85
Aplastic and Refractory		Massissaki A 440	
	Hamilton R, 59	Macciocchi A, 449	R
Anemias The, 343	Hanff PA, 275	Maclean IW, 72, 304	
Cortes HL, 425	Harrison WO, 28, 30, 314	Maggwa ABN, 6	Ray BS, 287
Crider SR, 314	Henrion RM, 441	Maggwa N, 304	Reichman RC, 271
Crocchiolo PB, 454	Hira SK, 167	Mahood J, 59	Rein MF, 24, 137
Curran J, 72	Holmes JR, 156	Maitha G, 6	Relier LB, 77

Vizconde LC, 382 Vosseler MG, 123

Reyes RR, 68
Ridgway GL, 432, 465
Robertson JA, 131
Ronald AR, 6, 72, 304
Rosey CE, 301
Ross MW, 119

S

Saensanoh C, 404 Saito I, 460 Sakellarides E, 398 Sanchez PL, 30 Sandstrom EG, 77, 366 Santambrogio A, 407 Santos C, 400 Satish DA, 164

Schachter J, 64
Scheibel JH, 32
Sherman H, 123
Short SL, 271
Siboulet A, 391
Sillis M, 10
Smith CD, 94
Solok V, 416
Soonthararak A, 404
Spicer DW, 94
Stamm WE, 18
Stockman DL, 271
Stolz E, 373, 379
Strugnell R, 1
Suvongse C, 148
Swenson CE, 64

Sylvestre M, 296

T
Taylor DN, 148
Theodoridis GC, 137
Thompson SE, 77
Torres CA, 382
Trupei MA, 271
Tupasi TE, 382
Turgeon P, 296
Turshen IJ, 137

V van Klingeren B, 364, 379 van Wijngaarden LJ, 364 van der Hoek J, 379 Vanhoof RL, 456 Vige PM, 441 W Westrom L, 437 White CC III, 137 Wolinsky SM, 271 Wong ES, 18

Y
Yunis AA, 340
Z
Zajdowicz TR, 28
Zwickl BW, 287

# INDEX OF SUBJECTS

Abscess, cutaneous gonococcal (Fiumara & Eisen), 34

Age, and risk of syphilis, gonorrhea, and pelvic inflammatory disease. in sexually active U. S. women (Bell & Holmes), 291

American Neisserian Medical Society (Kampmeier), 188

charter members of, 235

Committee for Survey of Research on the Gonococcus and Gonococcal Infections of, 260

constitution and bylaws of, 257

elected members of executive committees of, 234

officers of 232

programs of annual meetings of, 236

American Venereal Disease Association (Kampmeier), 185

awards by, 261

constitution and bylaws of, 262

elected members of executive committees of, 234

history of, appendices to, 231

epilogue to, 228

the interim or war years (1942-1947), 197

introduction to, 186

of the years of the American Neisserian Medical Society (1934-1942), 188

of the years of the American Venereal Disease Association (1947-1983), 200

officers of, 232

programs of annual meetings of, 239

Ampicillin, with probenecid, vs. rosoxacin, for gonorrhea (Cohen; Rein & Noble), 24

Anemia

aplastic, due to chemicals and drugs (Aksoy & others), 347 toxic etiology of (Cooperative Study Group for Aplastic and Refractory Anemias), 335

Antimicrobial agents

resistance to, by N. gonorrhoeae (Dillon & Pauzé), 353 worldwide (Causse), 333

Aplastic anemia

due to chemicals and drugs (Aksoy & others), 347

toxic etiology of (Cooperative Study Group for Aplastic and Refractory Anemias), 343

B

Bangkok, Thailand, role of H. ducreyi in penile ulcers in (Taylor & others), 148

C

Cefotaxime

for gonorrhea, vs. thiamphenicol (Notowicz & others), 379 for H. ducreyi infection, in Kenya (Plummer & others), 304 susceptibility of N. gonorrhoeae auxotypes to (Noble & Parekh), 152 Ceftizoxime, for urethritis caused by penicillinase-producing N. gon-

orrhoeae (Harrison & others), 30

Ceftriaxone, single-dose, for gonococcal conjunctivitis (Zajdowicz & others), 28

Cefuroxime

in vitro susceptibility of N. gonorrhoeae to, in Denmark-1979 (Bollerup), 308

susceptibility of N. gonorrhoeae auxotypes to (Noble & Parekh), 152 Centrifugation, Percoll density gradient, for purification of T. pallidum, Nichols strain (Hanff & others), 275

Chanchroid, male, thiamphenicol for (Latif; Crocchiolo & Lencioni),

Children, with gonorrheae; infections in sexual contacts and associates of (Alexander & others), 156

Chlamydia trachomatis

activity of thiamphenicol against (Ridgway & others), 432

and epididymitis (Kristensen & Scheibel), 32

(TRIC agent), infection with (Kampmeier), 169

upper genital tract infection with, and infertility, in mice (Swenson & Schachter), 64

Chloramphenicol, in vitro toxicity of, vs. thiamphenicol and nitrosochloramphenicol (Yunis), 340

Committee for Survey of Research on the Gonococcus and Gonococcal Infections, of American Neisserian Medical Society (Kampmeier), 260

Condoms, as barrier to herpes simplex infection transmission (Conant; Spicer & Smith), 94

Condylomata lata, of toewebs (Hira), 167

Conjunctivitis, gonococcal, single-dose ceftiraxone for (Zajdowicz & others), 28

Cutaneous gonococcal abscess (Fiumara & Eisen), 34

Denmark, in vitro susceptibility of N. gonorrhoeae to cefuroxime, penicillin, and tetracycline in, in 1979 (Bollerup), 308

DNA restriction endonuclease analysis, with EcoRI, for identification of herpes simplex viruses (Gerson; Portnoy & Hamelin), 85

Drug eruptions, fixed, on male genitalia (Pandhi & others), 164

E

EcoRI, DNA restriction endonuclease analysis with, for identification of herpes simplex viruses (Gerson; Portnoy & Hamelin), 85

Enteric pathogenic protozoa, in homosexual men from San Francisco, (Ortega & others), 59

Epididymitis (Krieger), 173

acute, and C. trachomatis, (Kristensen & Scheibel), 32

Erythromycin, susceptibility of N. gonorrhoeae auxotypes to (Noble & Parekh), 152

Gardnerella vaginalis, susceptibility of, to thiamphenicol, in nonspecific vaginitis (Hubrechts & others), 456

Genital herpes simplex infection, inapparent, in women at venereal disease clinic (Ferrer; Kraiselburd & Kouri), 91

Genital mycoplasmas, and N. gonorrhoeae, isolated from male urethra, coexistence of (Alfa & Robertson), 131

Genital tract

female, mixed infections of, thiamphenicol prophylaxis and treatment of (Moroni & others), 444

upper, chlamydial infection of, infertility after, in mice (Swenson & Schachter), 64

Genital ulcer disease, clinical diagnosis of, in men in tropics (Fast & others), 72

Gonococcal abscess, cutaneous (Fiumara & Eisen), 34

Gonococcal conjunctivitis, single-dose ceftriaxone for (Zajdowicz & others), 28

Gonococcal infection(s)

disseminated, and N gonorrhoeae serogroup (Sandström & others),

incidence of, with presence of AHU auxotype of N. gonorrhoeae (Noble & others), 68

thiamphenicol for, vs. penicillin and spectinomycin (Tupasi & others), 382

Gonococcal osteomyelitis (Black & Cohen), 96

Gonorrhea. See also Gonococcal infection(s); Neisseria gonorrhoeae case finding for, in asymptomatic men, cost-effectiveness analysis for (Pappius & others), 123

children with, infections in sexual contacts and associates of (Alexander & others), 156

clinical aspects of (discussion), 418

extragenital, thiamphenicol for (Calanchini & others), 398

microbial aspects of (discussion), 371

moxalactam for, with uncomplicated infection in women, (Jones; Ray & Zwickl), 287

rosoxacin vs. ampicillin plus probenecid for (Cohen; Rein & Noble), 24

in sexually experienced U. S. women, age-specific risks of (Bell & Holmes), 291

thiamphenicol for (Alessi; Monti & Santambrogio), 407

clinical trial of (Belda & others), 422

with extragenital infection (Calanchini & others), 398

one-minute (Siboulet & others), 391

single-dose (Mascaro & Capdevila), 388; (Murat & others), 414 in Kenya (Nsanze & others), 376

study of in 4,500 males (Santos), 400

with uncomplicated infection (Stolz), 373

intramuscular vs. oral route for (Panikabutra & others), 404 vs. spectinomycin (Kim), 386

vs. cefotaxime (Notowicz & others), 379

Gonorrhea contacts, management of, decision analytic approach to (Turshen & others), 137

Granuloma inguinale (Kampmeier), 318

H

Haemophilus ducreyi

infection with, in Kenya, cefotaxime for (Plummer & others), 304 in penile ulcers, in Bangkok, Thailand (Taylor & others), 148 primary isolation of, comparison of media for (Nsanze & others), 6 Herpes genitalis, as a clinical puzzle for two centuries (Kampmeier), 41 Herpes simplex infection; genital, inapparent, in women at venereal disease clinic (Ferrer, Kraiselburd & Kouri), 91

Herpes simplex virus(es)

identification of, by DNA restriction endonuclease analysis with EcoRI (Gerson; Portnoy & Hamelin), 85

transmission of, condom as barrier to (Conant; Spicer & Smith), 94 Homosexual men

N. meningitidis from pharynx of, N. gonorrhoeae inhibition by (Bisaillon & others), 296

partner numbers in, predictors of (Ross), 119

from San Francisco, enteric pathogenic protozoa in (Ortega & others),

sexually transmitted diseases in, rates of (Short & others), 271 single site N. gonorrhoeae infection in (Carlson & Haley), 312

1

Infertility

and chlamydial infection of upper genital tract in mice (Swenson & Schachter), 64

and sexually transmitted organisms (editorial) (Cates), 113

K

Kenva

H. ducreyi infection in, cefotaxime for (Plummer & others), 304 single-dose thiamphenicol for gonorrhea in (Nsanze & others), 376 Knolle, Jan Fryderyk, forgotten dissertation of on osseous syphilis (1763) (Lambert), 36

L

Leukocytes, polymorphonuclear, in urethritis diagnosis (Ayra & others), 10

M

Mice, infertility in, after chlamydial infection of upper genital tract (Swenson & Schachter), 64

Microbial resistance, worldwide, to antimicrobial agents (Causse), 333 Mouth. See Oral cavity

Moxalactam, for uncomplicated gonorrhea in women (Jones; Ray & Zwickl), 287

Mycoplasma(s), genital, and N. gonorrhoeae, isolated from male urethra, coexistence of (Alfa & Robertson), 131

Mycoplasma hominis, as human pathogen (Holmes), 159

N

Neisseria gonorrhoeae

activity of thiamphenicol against (Ridgway & others), 432

AHU auxotype of, incidence of disseminated gonococcal infection with (Noble & others), 68

auxotypes of, susceptibility of, to norfloxacin, cefotaxime, cefuroxime, and erythromycin (Noble & Parekh), 152

and genital mycoplasmas, isolated from male urethra, coexistence of (Alfa & Robertson), 131

infections with, single-dose thiamphenicol for (Oriel; Loo & Felmingham), 410

single site in homosexual men (Carlson & Haley), 312

penicillinase-producing, in vitro susceptibility of, to thiamphenicol, in Netherlands (van Klingeren; van Wijngaarden & Dessens-Kroon), 364

plasmid patterns of (van Klingeren; van Wijngaarden & Dessens-Kroon), 364

urethritis caused by, ceftizoxime for (Harrison & others), 30

penicillin G plus sulbactam vs. spectinomycin for (Crider & others), 314

from pharynx of homosexual men, in vitro inhibition of, by N. meningitidis (Bisaillon & others), 296

resistance of, to antimicrobials (Dillon & Pauze), 353

susceptibility of, to cefuroxime, penicillin, and tetracycline, in Denmark—1979 (Bollerup), 308

to rifampicin, correlation of with protein I determinants (Bygdeman; Mårdh & Sandström), 366

to thiamphenicol (Lind), 360

correlation of with protein I antigenic determinants (Bygdeman; Mårdh & Sandström), 366 in Netherlands (van Klingeren; van Wijngaarden & Dessens-Kroon), 364

serogrouping of, and disseminated gonococcal infection (Sandström & others). 77

urine as holding medium for (Rosey & Britt), 301

Neisseria meningitidis, from pharynx of homosexual men, inhibition of N. gonorrhoeae by (Bisaillon & others), 296

Nitroso-chloramphenicol, in vitro toxicity of, vs. thiamphenicol and chloramphenicol (Yunis), 340

Norfloxacin, susceptibility of N. gonorrhoeae auxotypes to (Noble & Parekh), 152

## 0

Oral cavity, warts of, management of (Fiumara), 267

Orchitis (Krieger), 173

Osseous syphilis, Knolle's forgotten dissertation on (1763) (Lambert), 36

Osteomyelitis, gonococcal (Black & Cohen), 96

#### F

Pelvic inflammatory disease

clinical aspects of (discussion), 463

hospitalized, in sexually experienced U. S. women, age-specific risks for (Bell & Holmes), 291

microbial etiology of (Mårdh), 428

microbiologic aspects of (discussion), 435

treatment of, in view of etiology and risk factors (Weström), 437

for gonococcal infections, vs. thiamphenicol and spectinomycin (Tupasi & others), 382

in vitro susceptibility of *N. gonorrhoeae* to, in Denmark—1979 (Bollerup), 308

Penicillin G, plus sulbactam, vs. spectinomycin, for urethritis caused by penicillinase-producing N. gonorrhoeae (Crider & others), 314

Penile ulcers, role of H. ducreyi in, in Bangkok, Thailand (Taylor & others), 148

Percoll density gradient centrifugation, for purification of *T. pallidum*, Nichols strain (Hanff & others), 275

Polymorphonuclear leukocytes, in urethritis diagnosis (Ayra & others), 10

Probenecid, with ampicillin, vs. rosoxacin, for gonorrhea, (Cohen; Rein & Noble), 24

Prostatitis syndromes, pathophysiology, diagnosis, and treatment of (Krieger), 100

Protozoa, enteric pathogenic, in homosexual men from San Francisco (Ortega & others), 59

Psychovenereology (editorial) (Ostrow), 182

### R

Rabbits, immunization of with S. aurantia, and nonresistance to T. pallidum (Graves; Drummond & Strugnell), I

Rifampicin, N. gonorrhoeae susceptibility to, correlation of with protein

I determinants (Bygdeman; Mardh & Sandström), 366

Rosoxacin, vs. ampicillin and probenecid, for gonorrhea (Cohen; Rein & Noble), 24

### S

Salpingitis, thiamphenicol for (Vigé & Henrion), 433; (Kunz & Macciocchi), 449

San Francisco, enteric pathogenic protozoa in homosexual men from (Ortega & others), 59

Sexually transmitted diseases

clinical aspects of (Petzoldt), 468

comparative rates of, among heterosexual men, homosexual men, and heterosexual women (Short & others), 271

microbiologic aspects of (Ridgway), 465

## Spectinomycin

vs. penicillin G plus sulbactam, for urethritis caused by penicillinaseproducing N. gonorrhoeae (Crider & others), 314

vs. thiamphenicol, for gonorrhea, (Kim), 386

vs. thiamphenicol and spectinomycin, for gonococcal infections, (Tupasi & others), 382

Spirocheta aurantia, rabbit immunization with, and nonresistance to T. pallidum (Graves; Drummond & Strugnell), 1

Sulbactam, with penicillin G, vs. spectinomycin, for urethritis caused by penicillinase-producing N. gonorrhoeae (Crider & others), 314

## **Syphilis**

osseous, Knolle's forgotten dissertation on (1763) (Lambert), 36 in sexually experienced U. S. women, age-specific risks of (Bell & Holmes), 291

#### T

Tetracycline, in vitro susceptibility of N. gonorrhoeae to, in Denmark— 1979 (Bollerup), 308

Thailand, role of *H. ducreyi* in penile ulcers in (Taylor & others), 148 Thiamphenicol

activity of, against C. trachomatis (Ridgway), 432

against N. gonorrhoeae, (Ridgway), 432

and aplastic anemia (Cooperative Study Group for Aplastic and Refractory Anemias), 335; (Aksoy & others), 347

for chanchroid, in males (Latif; Crocchiolo & Lancioni), 454

clinical pharmacokinetics and toxicity of (Ferrari), 328; (discussion), 351

for gonococcal infections, vs. penicillin and spectinomycin (Tupasi & others), 382

for gonococcal urethritis, current experience with (Akaydin & Solok), 416

male, minute treatment in water for (Belda & others), 422 study of 1,230 cases (Belda; dos Santos & Belda), 420

for gonorrhea (Alessi; Monti & Santambrogio), 407

with extragenital infection (Calanchini), 398

one-minute treatment (Siboulet & others), 391

oral vs. intramuscular (Panikabutra & others), 404

single-dose (Mascaro & Capdevila), 388; (Murat & others), 414 in Kenya (Nsanze & others), 376

study of 4,500 males (Santos), 400

vs. cefotaxime (Notowicz & others), 379

vs. spectinomycin (Kim), 386

with uncomplicated infection (Stolz), 373

in vitro susceptibility of N. gonorrhoeae to, in Netherlands, (van Klingeren; van Wijngaarden & Dessens-Kroon), 364

in vitro toxicity of, vs. chloramphenicol and nitroso-chloramphenicol (Yunis), 340

for mixed female genital tract infection, for prophylaxis and treatment (Moroni & others), 444

for N. gonorrhoeae infections, single-dose (Oriel; Loo & Felmingham), 410

N. gonorrhoeae susceptibility to, (Lind), 360

correlation of with protein I antigenic determinants (Bygdeman; Mardh & Sandström), 366 for nongonococcal urethritis, clinical evaluation of (Saito), 460 for salpingitis (Vigé & Henrion), 441; (Kunz & Macchiocchi), 449 susceptibility of anaerobic bacteria to (Finegold), 430 susceptibility of G. vaginalis to, in nonspecific vaginitis (Hubrechts

& others), 456

Toewebs, condylomata lata of (Hira), 167

Treponema pallidum

Nichols strain, purification of, by Percoll density gradient centrifugation (Hanff & others) 275

nonresistance to after immunization with S. aurantia, in rabbit (Graves; Drummond & Strugnell), 1

Tropics, clinical diagnosis of genital ulcer disease in men in (Fast & others), 72

U

Ulcer(s)

genital, clinical diagnosis of, in men in tropics (Fast & others), 72 penile, role of *H. ducreyi* in, in Bangkok, Thailand (Taylor & others), 148

Urethral smears, polymorphonuclear leukocytes in, and urethritis diagnosis (Ayra & others), 10

Urethritis

gonococcal, ceftizoxime for, (Harrison & others), 30

caused by penicillinase-producing N. gonorrhoeae, spectinomycin vs. sulbactam for (Crider & others), 314

diagnosis of, polymorphonuclear leukocyte counts in (Ayra & others), 10

thiamphenicol for, current experience with (Akaydin & Solok), 416 minute treatment in water for (Belda & others), 422

study of 1,230 male patients (Belda; dos Santos & Belda), 420 nongonococcal, thiamphenicol for, clinical evaluation of (Saito), 460 Urinary tract infections, in women at sexually transmitted disease clinic (Wong; Fennel & Stamm), 18

Urine, as holding medium for N. gonorrhoeae (Rosey & Britt), 301

V

**Vaginitis** 

nonspecific, incidence of among women at sexually transmitted diseases clinic (Embree; Caliando & McCormack), 81

susceptibility of G. vaginalis to thiamphenicol in (Hubrechts & others), 456

Verrucae. See Warts

W

Warts, of oral cavity, management of (Fiumara), 267

#### STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)

	Average No. Copies Each Issue during Preceding 12 Months	of Single Issues Published Nearest to Filing Date
A. Total No. Copies (Net Press Run)	3,080	3,030
B. Paid Circulation		
1. Sales through dealers and carriers, street		
vendors and counter sales	-	_
2. Mail Subscription	2,488	2,532
C. Total Paid Circulation	2,488	2,532
D. Free Distribution by Mail, Carrier or Other		
Means. Samples, Complimentary, and Other		
Free Copies	64	62
E. Total Distribution (Sum of C and D)	2,552	2,594
F. Copies Not Distributed		
1. Office use, left over, unaccounted,		
spoiled after printing	528	436
2. Return from News Agents	_	_
G. Total (Sum of E, F1, and 2-should equal		
net press run shown in A)	3,080	3,030

I certify that the statements made by me above are correct and complete.

Joseph W. Lippincott III, Associate Publisher

Date of Filing—October 1, 1984
Title of Publication—Sexually Transmitted Diseases
Publication No. 371350
Frequency of Issue—Quarterly: Jan-March, April-June, July-Sept, Oct-Dec
Subscription Price—\$39.00

Subscription Price—\$39.00 Location of Known Office of Publication—2350 Virginia Avenue, Hagerstown, MD 21740

Location of the Headquarters of General Business Offices of the Publishers—East Washington Square, Philadelphia, PA 19105 Publisher—American Venereal Disease Association, East Washington Square, Philadelphia, PA

19105 Editor---William M. McCormack, MD, Downstate Medical Center, 450 Clarkson Avenue,

Brooklyn, NY 11203

Managing Editor—Deborah G. Huey, East Washington Square, Philadelphia, PA 19105

Owner—American Venereal Disease Association, Box 22349, San Diego, CA 92122
Known Bondholders, Mortenees and Other Security Holders Owning or Holding 15 or

Known Bondholders, Mortgages and Other Security Holders Owning or Holding 1% or More of Total Amount of Bonds, Mortgages or Other Securities—None

The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes has not changed during preceding 12 months.